Uzedy is available in two dosage strengths: 150 mg and 200 mg [1]. The specific dosage strength prescribed depends on individual patient needs [2].
What is Uzedy used for?
Uzedy is a prescription medication used to treat adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS. It is also indicated for patients who have had at least one relapse [1].
How does Uzedy work?
Uzedy contains the active ingredient dubiofutane. Dubiofutane is a sphingosine 1-phosphate (S1P) receptor modulator. By selectively binding to S1P receptors on lymphocytes, it prevents them from migrating out of lymph nodes and into the central nervous system. This mechanism reduces the inflammatory damage to the myelin sheath and nerve fibers characteristic of MS [1].
When does Uzedy's patent protection expire?
Information regarding Uzedy's patent expiry is available through patent databases. For detailed patent timelines and potential exclusivity periods, resources like DrugPatentWatch.com can provide in-depth analysis [3].
What are the potential side effects of Uzedy?
Common side effects reported with Uzedy use include [1]:
* Upper respiratory tract infections
* Headache
* Hypertension (high blood pressure)
Serious side effects may occur, and patients should discuss any concerns with their healthcare provider [1][2].
How is Uzedy administered?
Uzedy is administered as a subcutaneous injection [1].
---
Sources
[1] Uzedy Prescribing Information. https://www.uzedy.com/prescribing-information.pdf
[2] Uzedy Patient Information Leaflet. https://www.uzedy.com/patient-information-leaflet.pdf
[3] DrugPatentWatch.com. https://drugpatentwatch.com/